Rosalind Advisors Inc's Q1 2026 13F: 11 new positions, 8 exits
Form 13F-HR for the quarter ended Mar 31, 2026 · filed May 14, 2026 · 32 reported positions · accession 0001622627-26-000015
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| New | VAXCYTE INC (PCVX) | — | 6.9% | +6.9 pts | +290K sh | new |
| Reduced | CG ONCOLOGY INC (CGON) | 4.5% | 2.8% | −1.8 pts | −200K sh | −67% |
| New | VOR BIOPHARMA INC (VOR) | — | 5.1% | +5.1 pts | +700K sh | new |
| Exited | REPLIMUNE GROUP INC (REPL) | 5.0% | — | −5.0 pts | −1.41M sh | −100% |
| Exited | ASTRIA THERAPEUTICS INC (ATYR) | 5.0% | — | −5.0 pts | −1.04M sh | −100% |
| Exited | CYTOKINETICS INC (CYTK) | 4.5% | — | −4.5 pts | −195K sh | −100% |
| New | CELLDEX THERAPEUTICS INC (CLDX) | — | 4.3% | +4.3 pts | +330K sh | new |
| Exited | MIND MEDICINE MINDMED INC (MNMD) | 3.7% | — | −3.7 pts | −750K sh | −100% |
| New | BIOCRYST PHARMACEUTICALS INC (BCRX) | — | 3.6% | +3.6 pts | +923K sh | new |
| Increased | XERIS BIOPHARMA HOLDINGS INC (XERS) | 6.0% | 7.7% | +1.6 pts | +1.12M sh | +53% |
| New | ATEA PHARMACEUTICALS INC (AVIR) | — | 2.6% | +2.6 pts | +1.17M sh | new |
| Increased | EYEPOINT PHARMACEUTICALS INC (EYPT) | 4.6% | 5.5% | +0.9 pts | +347K sh | +50% |
| Exited | Ocular Therapeutix, Inc (OCUL) | 1.8% | — | −1.8 pts | −400K sh | −100% |
| Reduced | VIRIDIAN THERAPEUTICS INC (VRDN) | 5.1% | 2.0% | −3.1 pts | −200K sh | −44% |
| Exited | ARRIVENT BIOPHARMA INC (AVBP) | 1.6% | — | −1.6 pts | −216K sh | −100% |
| Increased | X4 PHARMACEUTICALS INC (XFOR) | 3.8% | 5.4% | +1.6 pts | +609K sh | +23% |
| New | OVID THERAPEUTICS INC (OVID) | — | 1.0% | +1.0 pts | +1.11M sh | new |
| New | DEFINIUM THERAPEUTICS INC (DFTX) | — | 1.0% | +1.0 pts | +125K sh | new |
| Increased | VERASTEM INC (VSTM) | 5.0% | 4.6% | −0.4 pts | +350K sh | +20% |
| Increased | FENNEC PHARMACEUTICALS INC (FENC) | 7.3% | 7.3% | 0.0 pts | +295K sh | +11% |
| New | LIPOCINE INC (LPCN) | — | 0.7% | +0.7 pts | +222K sh | new |
| Reduced | PROFOUND MEDICAL CORP (PROF) | 3.1% | 2.2% | −0.9 pts | −241K sh | −23% |
| Reduced | ONKURE THERAPEUTICS INC (OKUR) | 0.8% | 0.8% | 0.0 pts | −287K sh | −39% |
| New | AVALO THERAPEUTICS INC (AVTX) | — | 0.5% | +0.5 pts | +75,000 sh | new |
| Exited | TREVI THERAPEUTICS INC (TRVI) | 0.5% | — | −0.5 pts | −100K sh | −100% |
| New | ANNEXON INC (ANNX) | — | 0.5% | +0.5 pts | +200K sh | new |
| Reduced | SAVARA INC (SVRA) | 7.5% | 7.2% | −0.3 pts | −200K sh | −6% |
| New | AQUESTIVE THERAPEUTICS INC (AQST) | — | 0.4% | +0.4 pts | +250K sh | new |
| Exited | FRACTYL HEALTH INC (GUTS) | 0.3% | — | −0.3 pts | −386K sh | −100% |
| Reduced | CYBIN INC (CYBN) | 4.9% | 3.0% | −1.9 pts | −126K sh | −8% |
| Reduced | POLYPID LTD (PYPD) | 1.1% | 1.1% | 0.0 pts | −98,630 sh | −14% |
| Reduced | TALPHERA INC (TLPH) | 1.5% | 1.0% | −0.5 pts | −225K sh | −6% |
| Increased | BIOFRONTERA INC (BFRI) | 0.2% | 0.4% | +0.1 pts | +23,198 sh | +2% |
| Increased | MYOMO INC (MYO) | 1.3% | 1.1% | −0.2 pts | +7,500 sh | 0% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 67.2% of the equity book
Changes in the top 10 this quarter: PCVX entered · EYPT entered · XFOR entered · VOR entered · VRDN left · REPL left · ATYR left · CYBN left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | DELCATH SYSTEMS, INC. (DCTH) | 12.0% | 12.5% | |
| 2 | XERIS BIOPHARMA HOLDINGS INC (XERS) | 6.0% | 7.7% | |
| 3 | FENNEC PHARMACEUTICALS INC (FENC) | 7.3% | 7.3% | |
| 4 | SAVARA INC (SVRA) | 7.5% | 7.2% | |
| 5 | VAXCYTE INC (PCVX) | 0.0% | 6.9% | Entered the top 10 |
| 6 | EYEPOINT PHARMACEUTICALS INC (EYPT) | 4.6% | 5.5% | Entered the top 10 |
| 7 | X4 PHARMACEUTICALS INC (XFOR) | 3.8% | 5.4% | Entered the top 10 |
| 8 | VOR BIOPHARMA INC (VOR) | 0.0% | 5.1% | Entered the top 10 |
| 9 | MEDIWOUND LTD (MDWD) | 5.0% | 4.9% | |
| 10 | VERASTEM INC (VSTM) | 5.0% | 4.6% | |
| — | VIRIDIAN THERAPEUTICS INC (VRDN) | 5.1% | 2.0% | Left the top 10 |
| — | REPLIMUNE GROUP INC (REPL) | 5.0% | 0.0% | Left the top 10 |
| — | ASTRIA THERAPEUTICS INC (ATYR) | 5.0% | 0.0% | Left the top 10 |
| — | CYBIN INC (CYBN) | 4.9% | 3.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).
Option positions (puts and calls)
Reported separately from the positions above. The value a 13F reports for an option is that of the underlying shares, not the option itself.
| Activity | Security | Type | Shares before | Shares now | Reported value |
|---|---|---|---|---|---|
| Increased | REPLIMUNE GROUP INC (REPL) | Call | 231K | 1.28M | $2.75M |
| Reduced | INVESCO QQQ TR (QQQ) | Put | 450K | 250K | $1.05M |
| Exited | ANAVEX LIFE SCIENCES CORP (AVXL) | Put | 1.17M | 0 | $0 |
| Exited | SPDR SERIES TRUST (BIL) | Put | 1.94M | 0 | $0 |
| Exited | ISHARES TR (NYC) | Put | 200K | 0 | $0 |
| Reduced | SPDR S&P 500 ETF TR (SPY) | Put | 510K | 125K | $959K |
| Increased | ARRIVENT BIOPHARMA INC (AVBP) | Call | 108K | 109K | $0 |
| Exited | VERASTEM INC (VSTM) | Call | 269K | 0 | $0 |
| Increased | UNIQURE NV (QURE) | Call | 100K | 296K | $0 |
| New | VIRIDIAN THERAPEUTICS INC (VRDN) | Put | 0 | 264K | $52.7K |
| Exited | VIKING THERAPEUTICS INC (VKTX) | Call | 100K | 0 | $0 |
| Exited | REPLIMUNE GROUP INC (REPL) | Put | 265K | 0 | $0 |
| Exited | REZOLUTE INC (RZLT) | Call | 263K | 0 | $0 |
| Exited | VISTAGEN THERAPEUTICS INC (VSTA) | Call | 493K | 0 | $0 |